Buy - Price 43.75 on Jan. 22 by Punk Ziegel & Co. BK reported 4Q earnings of 45 cents a share -- well below estimate and 3Q -- due to a series of one-time events. The estimates for the next three years are being raised as follows: 2008E increases to $2.93 a share from $2.89; 2009E is being raised to $3.24 a share from $3.14; and 2010E is $3.53...The setback the company experienced in balance-sheet [management] is not expected to be a material event in the next few quarters or years. Market-cap: $35 billion.

Buy - Price 25.36 on Jan. 22 by Think Equity This leading Internet audience-measurement and marketing-intelligence firm's [advantages include]: its leadership of a $240 million market that we expect will grow 20% annually for the next several years and... significant barriers to entry, plus a highly predictable revenue model. Target: 36, based on 25 times 2009E Ebitda [earnings before interest, taxes, depreciation and amortization of] $35 million. Market-cap: $760 million.

Buy - Price 66.29 on Jan. 22 by Hilliard Lyons Aided by Pfizer Consumer Healthcare unit acquisition, consumer-segment sales jumped 49%; currency added 5% to growth in the quarter [and] offset lower anemia-treatment revenue and declining drug-coated stent sales. Sales for 2007 grew 15%, to $61.1 billion. We view JNJ's diverse business mix positively. Strong finances allow for share repurchases, dividend growth, and acquisitions such as consumer health care; 72 target is based on our 2008 EPS forecast. Market-cap: $187 billion.

Accumulate - Price 15.23 on Jan. 22 by CL King Reducing our target price to 20 (from 22) [based on a price/earnings ratio] value of 13.9 times, using our FY08 EPS estimate of $1.44 -- 15% above the group average of 12.1 times. While the market headwinds facing consumers and retail...have caused E-EPS reductions, we believe the company should benefit from recoveries in execution, reduced technology spending and associated risks, better marketing, reduced inventory levels, continued expansion of its concepts and greater clarity of the international opportunity.

Market Outperform - Price 17.06 on Jan. 23 by Avondale Partners Luminex announced it has signed a collaboration agreement with Tyson Foods, the world's largest processor of chicken, beef and pork, to develop animal-health and food-safety tests using its xMAP technology (sold to research labs as well as pharmaceutical, diagnostic, and biotechnology companies worldwide). Although initially focused on human-health testing, LMNX has made clear its strategic interest in expanding its technology's use...Maintaining 22 target. Market-cap: $624 million.

Hold - Price 12.08 on Jan. 22 by Wedbush Morgan PETS [again] generated solid new customer growth. For FY08, we are lowering revenue estimate to $188 million from $193 million, but increasing E-EPS to 79 cents from 75...PETS may benefit from consumers' seeking more affordable pet medications. Maintaining 13 target, [based on] multiple of 16 times our FY09 EPS estimate of 82 cents, in line with PETS' projected three-year earnings-growth rate. Market-cap: $313 million.

Peer Perform - Price 79.52 on Jan. 22 by Bear Stearns Following an earnings miss ($1.11 versus $1.13 consensus) on declining margins...[we] expect pressure on SLB shares to continue near-term...we believe [this] makes SLB more reasonably valued...We expect the current 2008 consensus EPS estimate of $5.02 to decline to the $4.80-to-$4.90 range...We believe long-term prospects remain robust, despite a disappointing 4Q07 performance and management's efforts to dampen Wall Street's lofty '08 expectations. That said, SLB still appears expensive at a 28% premium on 2008 P/E and a 45% premium on 2008 enterprise-value/Ebitda to its peers. Market-cap: $92.2 billion.

Neutral - Price 4.40 on Jan. 22 by Merriman Curhan Ford Management's decision to suspend FY08 guidance [may show doubt about] previous guidance of $300 million in sales and 40 cents in EPS...We remain optimistic that SWHC will enter FY09 in a much stronger position, driven by extra time [for marketing] new shotgun and hunting-rifle lines...[and want to see] clearer signs of improving industry sales or pending military contracts before adding to positions at these lower levels. Downgraded from Buy. Market-cap: $161 million.